
Anh T Le

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9202309/publications.pdf Version: 2024-02-01



IF # ARTICLE CITATIONS Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nature Medicine, 2013, 19, 1469-1472. TRKing Down an Old Oncogene in a New Era of Targeted Therapy. Cancer Discovery, 2015, 5, 25-34. 9 9.4 509 Resistance Mechanisms to Targeted Therapies in <i>ROS1</i>+ and <i>ALK</i>+ Nonâ€"small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 3334-3347. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non–Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. Journal of Thoracic Oncology, 2018, 13, 4 1.1 119 1717-1726. Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases. Journal of Pharmacology and Experimental Therapeutics, 2018, 364, 494-503. 2.5 An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer. Journal of 6 1.1 71 Thoracic Oncology, 2016, 11, 1273-1281. EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. Cancer Research, 2017, 77, 3551-3563. Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family 8 7.0 52 Oncogenes. Clinical Cancer Research, 2021, 27, 1463-1475. The Democratization of the Oncogene. Cancer Discovery, 2014, 4, 870-872. 9.4 10 Oncogenic Fusions Involving Exon 19 of ALK. Journal of Thoracic Oncology, 2012, 7, e44. 1.1 6 Novel Human-Derived RET Fusion NSCLC Cell Lines Have Heterogeneous Responses to RET Inhibitors and 2.3 Differential Regulation of Downstream Signaling. Molecular Pharmacology, 2021, 99, 435-447. Incidence of ERBB gene fusions (EGFR, ERBB2, ERBB4) across tumor types.. Journal of Clinical 12 0 1.6 Oncology, 2021, 39, 3091-3091.